Supplement
Lithuanian HESS registry Lithuania has a national haematological disease monitoring system (HESS), which collects data from 2000 and covers the entire country, with a population of 3 million. Patients with haematological malignancies are managed in 5 centres across the country and all physicians and pathologists are obliged to report all newly diagnosed CML cases to HESS Registry. HESS contains data on age, sex, ICD-10 code, date of diagnosis, clinical symptoms, laboratory test, risk group, treatment, Ph and BCR-ABL status (both mandatory from 2010) of CML. Through unique personal ID, HESS is also linked to the national death registry, which allows further validation of data. All Lithuanians are covered by national healthcare insurance and haematological diseases are treated in public healthcare system. Therefore underreporting to HESS registry is unlikely. All patients, who were diagnosed with CML (ICD-10 code 92.1) between January 1st 2000 and December 31st 2013, were entered into the study. There was no age restriction or other exclusion criteria.
Statistical methods
Crude and age standardize rates according to world population (CR and ASR (W), respectively) were calculated for incidence, prevalence and mortality. CR was represented as the number of patients per 100 000 inhabitants per year in Lithuania [1] . ASR (W) was defined as a weighted mean of the age-specific rates [2] ; the weights were taken from the standard world population [3] . Incidence rate was defined as the number of new CML cases that occurred during a given time period [1] . Mortality rate was defined as a number of deaths from any cause during a given time period [1] . Relative survival rate (RSR) was defined as observed survival in CML group divided by the expected survival of a comparable group from general population [4] . One-, five-and ten-year RSRs with 95% confidence intervals (95% CI) were estimated. Survival time was calculated as the time from the date of diagnosis to death; 31st of December 2014 was set as censoring date for alive patients. Survival trends were evaluated by Kaplan-Meier method. Log-rank test was used evaluate statistical difference between Kaplan-Meier curves. All statistics were performed by Statistical Analysis System (SAS) package version 9.2. A twotailed p-value less than 0.05 was considered significant. 0-17 years  ---------18-60 years  ---------61+ years  ---------Overall  ---------Table S8 . Kaplan-Meier analysis of Chronic Myeloid Leukemia. All patients Figure S3 . Kaplan-Meier diagram of Chronic Myeloid Leukemia: >60 year old patients. 
